Clinical Trials
16 trialsNCT01909934 2025-09-19
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Takeda
Phase 4 Completed
NCT00168727 2023-08-23
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Biogen
Phase 4 Completed
NCT00003398 2019-10-17
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Phase 4 Completed
NCT01180049 2019-05-20
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Pfizer
Phase 4 Completed
NCT00430352 2017-08-14
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Hoffmann-La Roche
Phase 4 Completed
NCT02782845 2016-11-21
An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)
Hoffmann-La Roche
Phase 4 Completed
NCT00352703 2014-11-03
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
Swedish Orphan Biovitrum
Phase 4 Completed
NCT00808171 2014-07-29
Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture
Federal University of Minas Gerais
Phase 4 Completed
NCT01164475 2014-02-25
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
Sanofi
Phase 4 Completed
NCT00969462 2013-07-01
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma
Meir Medical Center
Phase 4 Completed
NCT00926757 2013-05-29
HBVNHL
Taipei Veterans General Hospital, Taiwan
Phase 4 Completed
NCT00114348 2013-02-04
ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia
Charite University, Berlin, Germany
Phase 4 Completed
NCT00162955 2012-05-08
Prevention of CHOP-induced Chronic Cardiotoxicity
Osaka City University
Phase 4 Completed
NCT00277160 2010-10-08
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
Amgen
Phase 4 Completed
NCT01124526 2010-05-17
Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
Asociacion Espanola de Hematologia y Hemoterapia
Phase 4 Completed
NCT00090038 2009-10-20
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
Biogen
Phase 4 Completed